Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma

BACKGROUND: Due to the hypervascular nature of glioblastoma (GBM), antiangiogenic treatments, such as vatalanib, have been added as an adjuvant to control angiogenesis and tumor growth. However, evidence of progressive tumor growth and resistance to antiangiogenic treatment has been observed. To cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Shankar, Adarsh, Borin, Thaiz F, Iskander, Asm, Varma, Nadimpalli RS, Achyut, Bhagelu R, Jain, Meenu, Mikkelsen, Tom, Guo, Austin M, Chwang, Wilson B, Ewing, James R, Bagher-Ebadian, Hassan, Arbab, Ali S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790509/
https://www.ncbi.nlm.nih.gov/pubmed/27022280
http://dx.doi.org/10.2147/OTT.S93790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790509/
https://www.ncbi.nlm.nih.gov/pubmed/27022280
http://dx.doi.org/10.2147/OTT.S93790

Ejemplares similares